[U: UBS’s Target Still Above Mine!] Moderna Jumps Over 13% On First US Bird Flu Fatality. Hard News.

UPDATE: On January 8, 2025, UBS Securities reduced its price targets on several pharma / bio-science companies, including Merck and Moderna (citing a coming Tangerine 2.0 imagined onslaught). Yawn. You see, in the case of Moderna, the reduced one year target at UBS is $96, which is $11 higher than my guess of $85. Bob’s your uncle. [And, in the case of Merck, the target now stands at $130, same as mine.] End updated portion.

Here two days later, Moderna’s stock price is still increasing.

The reason is rather morose: the bird flu death we mentioned in Louisiana. Moderna is likely to benefit from any vaccines contracts let by the federal government. We’ve suggested it will be an $85 stock by this time next year; and today it sits $46. We shall see. Here’s the latest:

…Moderna is one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, which is spreading rapidly through farm- and wild animals….

As we say… we shall see.

नमस्ते